Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome p450

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 1, 1998, Pages 381-388

  Voorman, Richard L ^a,b   Maio, Stephen M ^a   Payne, N Ann ^a   Zhao, Zhiyang ^a   Koeplinger, Kenneth A ^a   Wang, Xiaohong ^a  

^a Drug Metab and Disposition Research   (United States)

^b Pharmacia and Upjohn   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6' HYDROXYDELAVIRDINE; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DELAVIRDINE; DRUG METABOLITE; ERYTHROMYCIN; GLUTATHIONE; KETOCONAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIAZOLAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; DEALKYLATION; DOSE TIME EFFECT RELATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; LIVER MICROSOME; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DELAVIRDINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; KINETICS; MALE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032454713     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Adams WJ, Hosley JD, Sedlock ML, Anstadt RA, Romero DL, Morozowich W, Smith DP and Douglas SL (1996) Pharmacokinetics, oral bioavailability and dose proportionality of the HIV-1 reverse transcriptase inhibitor delavirdine in the male Sprague-Dawley rat. ISSX Proc 10:428.
2. Borin MT, Chambers JH, Carel BJ, Gagnon S and Freimuth WW (1997) Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 61:544-553.
3. Chang M, Sood VK, Wilson GJ, Kloosterman DA, Sanders PE, Hauer MJ and Fagerness PE (1997) Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug Metab Dispos 25:228-242.
4. Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL and Stetson PL (1997) Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther 61: 531-543.
5. Chiba M, Nishime JA and Lin JH (1995) Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275: 1527-1534.
6. Correia MA (1991) Cytochrome P450 turnover. Methods Enzymol 206:315-325.
7. Cox SR, Batts DH, Ward P, Freimuth WW, Staton BA, Peel BG and et al (1993) Escalating single and multiple dose safety, tolerance and pharmacokinetics (PK) of delavirdine mesylate (DLV, U-90152S) in normal volunteers [abstract]. National Conference on Human Retroviruses and Related Infections, December 12-16, 1993, p 158.
8. Damani LA, Crooks PA, Shaker MS, Caldwell J, D'Souza J and Smith RL (1982) Species differences in the metabolic C- and N-oxidation and N-methylation of [14C]pyridine in vivo. Xenobiotica 12:527-534.
9. Decker CJ, Rashed MS, Baillie TA, Maltby D and Correia MA (1989) Oxidative metabolism of spironolactone: evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P450. Biochemistry 28:5128-5136.
10. Declercq E (1994) How to overcome resistance of HIV-1 to HIV-1-specific reverse transcriptase inhibitors. AIDS 8:1020-1021.
11. Desai D, Kagan SS, Amin S, Carmella SG and Hecht SS (1993) Identification of 4-(methylnitrosamino)-1-[3-(6-hydroxypyridyl)]-1-butanone as a urinary metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in rodents. Chem Res Toxicol 6:794-799.
12. Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M, Resnick L, Mayers D, Lane J, Aristoff PA, Thomas RC and Tarpley WG (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 37:1127-1131.
13. Gorrod JW and Aislaitner G (1994) The metabolism of alicyclic amines to reactive iminium ion intermediates. Eur J Drug Metab Pharmcokinet 19:209-217.
14. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371.
15. Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249.
16. Kronbach T, Mathys D, Umeno M, Gonzalez FJ and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
17. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656.
18. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
19. Lopez Garcia MP, Dansette PM and Mansuy D (1994) Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 33:166-175.
20. Lu A and Levin W (1972) Partial purification of cytochrome P-450 and cytochrome P-448 from rat liver microsomes. Biochem Biophys Res Commun 46:1334-1339.
21. Mani C, Pearce R, Parkinson A and Kupfer D (1994) Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 15:2715-2720.
22. Masubuchi Y, Narimatsu S, Hosokawa S and Suzuki T (1994) Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats. Biochem Pharmacol 48:1891-1898.
23. Miyata M, Nagata K, Shimada M, Yamazoe Y and Kata R (1994) Structure of a gene and cDNA of a major constitutive form of testosterone 6beta-hydroxylase (P450/ Gbeta) encoding CYP3A2: Comparison of the cDNA with P450PCN2. Arch Biochem Biophys 314:351-359.
24. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes: Evidence for its hemeprotein nature. J Biol Chem 239:2379-2385.
25. Prough RA and Ziegler DM (1977) The relative participation of liver microsomal amine oxidase and cytochrome P450 in N-demethylase reactions. Arch Biochem Biophys 180:363-373.
26. Redinbaugh MG and Turley RB (1986) Adaptation of the bicinchoninic acid protein assay for use with microtitre plates and sucrose density gradient fractions. Anal Biochem 153:267-276.
27. Reinerink EJ, Doorn L, Jansen EH and Van Iersel AA (1991) Measurement of enzyme activities of cytochrome P-450 isoenzymes by high-performance liquid chromatographic analysis of products. J Chromatogr 553:233-241.
28. Rosenberg ZF and Fauci AS (1991) Immunopathogenesis of HIV infection. FASEB J 10:2382-2390.
29. Sadrieh N and Thomas PE (1994) Characterization of rat cytochrome P450 isozymes involved in the covalent binding of cyclosporin A to microsomal proteins. Toxicol Appl Pharmacol 127:222-232.
30. Schneck DW and Pritchard JF (1981) The inhibitory effect of propranolol pretreatment on its own metabolism in the rat. J Pharmacol Exp Ther 218:575-581.
31. Schuetz EG, Beck WT and Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
32. Silverman RB (1988) Mechanism-Based Enzyme Inactivitation: Chemistry and Enzymology, vol. 1, pp. 3-25. CRC Press, Boca Raton, FL.
33. Tassaneeyakul W, Birkett DJ, Veronese ME, Mcmanus ME, Tukey RH and Miners JO (1994) Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 4:281-284.
34. vanderHoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
35. Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne NA and Ackland MJ (1998) Metabolism of delavirdine, an HIV-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats and other species: Probable involvement of CYP3A subfamily. Drug Metab Dispos, 26:631-639.
36. Weber C, Stoeckel K and Lalka D (1994) Accumulation kinetics of propranolol in the rat: comparison of the Michaelis-Menten-mediated clearance and clearance changes consistent with the altered enzyme hypothesis. Pharmaceut Res 11:420-425.
37. Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase CF 2d, Schroeder MC, Kunze KL and Trager WF (1993) Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Drug Metab Dispos 21:874-882.